Atormac
briv
Neurology India
menu-bar5 Open access journal indexed with Index Medicus
  Users online: 22650  
 Home | Login 
About Editorial board Articlesmenu-bullet NSI Publicationsmenu-bullet Search Instructions Online Submission Subscribe Videos Etcetera Contact
  Navigate Here 
 Search
 
  
 Resource Links
  »  Similar in PUBMED
 »  Search Pubmed for
 »  Search in Google Scholar for
 »Related articles
  »  Article in PDF (1,268 KB)
  »  Citation Manager
  »  Access Statistics
  »  Reader Comments
  »  Email Alert *
  »  Add to My List *
* Registration required (free)  

 
  In this Article
 »  Abstract
 » Methods
 » Results
 » Discussion
 » Conclusion
 »  References
 »  Article Figures
 »  Article Tables

 Article Access Statistics
    Viewed947    
    Printed18    
    Emailed0    
    PDF Downloaded20    
    Comments [Add]    

Recommend this journal

 


 
Table of Contents    
REVIEW ARTICLE
Year : 2021  |  Volume : 69  |  Issue : 6  |  Page : 1524-1538

Lamotrigine-Associated Movement Disorder: A Literature Review


Department of Neurology; Departments of Medicine, Federal University of Santa Maria, Santa Maria, Rio Grande do Sul, Brasil

Date of Submission19-Dec-2019
Date of Decision12-Mar-2020
Date of Acceptance05-Jun-2020
Date of Web Publication23-Dec-2021

Correspondence Address:
Dr. Jamir Pitton Rissardo
Rua Roraima, Santa Maria, Rio Grande do Sul
Brasil
Login to access the Email id

Source of Support: None, Conflict of Interest: None


DOI: 10.4103/0028-3886.333440

Rights and Permissions

 » Abstract 


Background: Lamotrigine (LMT) is a phenyltriazine derivative that was originally described as an antiepileptic drug.
Objective: This literature review aims to evaluate the clinical epidemiological profile, pathological mechanisms, and management of lamotrigine-associated movement disorders.
Methods: Relevant reports in six databases were identified and assessed by two reviewers without language restriction. Reports that the individuals only developed tremor or ataxia after LMT use were not included.
Results: In total 48 reports of 108 cases from 19 countries were assessed. The movement disorders associated with LMT found were 29 tics, 21 dyskinesias, 14 myoclonus, 13 parkinsonism, 10 dystonia, and 1 stuttering. The not clearly defined cases included 10 akathisia, 4 myoclonus, 4 cerebellar syndromes, 1 hypertonia, 1 dyskinesia, and an unknown number of dystonia cases. The mean reported age was 33.34 years (range: 1.574 years). The male was the predominant sex and the most common LMT indication was epilepsy. The mean LMT-dose at the movement disorder onset was 228 mg. The time from LMT start to the onset of movement disorder was within 6 months in 81%. The time from LMT withdrawal to complete recovery was within 1 month in 83%. The most common management was LMT withdrawal.
Conclusions: In the literature, the majority of the cases did not give a clear picture of the individual, and the times of movement disorder onset and recovery are not described. We believe that before withdrawal LMT, a dose adjustment based on the benefits and adverse events with careful evaluation case-by-case can be done.


Keywords: BW430C, drug-induced, lamotrigine, movement disorder, review
Key Messages: 1) LMT-induced DTN and DKN are probably related with GABA; MCL with GABA and Glutamate; PKN and tic with glutamate. 2) The type of LMT-induced movement disorder may be associated with the LMT-dose. 3) When LMT-induced tics are observed; we believe that before withdrawal LMT, a dose adjustment based on the benefits and adverse events with careful evaluation case-by-case can be done.


How to cite this article:
Rissardo JP, Fornari Caprara AL. Lamotrigine-Associated Movement Disorder: A Literature Review. Neurol India 2021;69:1524-38

How to cite this URL:
Rissardo JP, Fornari Caprara AL. Lamotrigine-Associated Movement Disorder: A Literature Review. Neurol India [serial online] 2021 [cited 2022 Jan 20];69:1524-38. Available from: https://www.neurologyindia.com/text.asp?2021/69/6/1524/333440




Lamotrigine (LMT) is a phenyltriazine derivative that was originally described as an antiepileptic drug [Figure 1]. The first chemical studies with this drug started in the decade of 1980 by scientists at Wellcome Laboratories; in the same decade, in animal models, LMT was found to have considerable anticonvulsant activity.[1] After extensive publishing data about efficacy and safety, LMT was first approved in Ireland in 1990.[2] Only four years later, approved by the Food and Drug Administration for adjunctive use in epilepsy in the United States. It is worthy of mentioning that it was noted in epileptic patients that LMT improved mood; after these occasional results, studies have begun to assess the efficacy of LMT in bipolar disorder.[3]
Figure 1: Skeletal formula of the anticonvulsant drug lamotrigine, also known as 3,5-diamino-6-(2,3-dichlorophenyl)-1,2,4-triazine

Click here to view


LMT is approved for adjunctive therapy into partial-onset seizures, primary generalized tonic-clonic seizures, generalized seizures of Lennox-Gastaut syndrome; conversion to monotherapy in adolescents with partial-onset seizures; maintenance treatment of bipolar type I disorder.[4] The off-label uses include acute bipolar depression, fibromyalgia, migraines, peripheral neuropathy, neuropathic pain, restless legs syndrome, schizophrenia, and unipolar depression.[4],[5]

The mechanism of action of LMT is not entirely understood, but the main actions are in the presynaptic antagonism of type 2 voltage-gated sodium channels (preferentially to the inactivated state) and high-voltage-activated calcium channels.[4] The blockade of these channels modulates the release of glutamate/aspartate and γ-aminobutyric acid (GABA).[6] The decrease of glutamate/aspartate leads to an increase of serotonin neuronal firing, which is one of the explanations for the use of LMT associated with antidepressants as an augmentation agent.[7] The GABA modulation is more complex and is dependent on the site of action; for example, LMT decreased the release of GABA in the amygdala, but increases in the entorhinal cortex [Figure 2].[6],[7],[8],[9],[10]
Figure 2: Schematic diagram of the mechanism of action of lamotrigine (LMT). After administration, LMT goes to the liver; from that, LMT can pass the blood-brain barrier. LMT is a substrate for SLC22A1 (A and B). ATP-binding cassette superfamily of transporters in LMT efflux, which include ABCB1, ABCC2, and ABCG2 (C). LMT antagonizes voltage-gated sodium channels (1) and calcium channels (2). Sodium channels are related to the stabilization of presynaptic neuronal membranes (3) and the interference in the calcium-complex (4). These actions lead to a decrease of glutamate and aspartate, which increases serotonin neuronal firing. Also, LMT can lead to an increase/decrease of GABA depending on the action's site

Click here to view


The side effects of this anticonvulsant that occur in more than ten percent of the individuals are ataxia, blurred vision, diplopia, dizziness, headache, nausea, pharyngitis, rash, rhinitis, and somnolence.[4] There is a boxed warning by the FDA about cases of life-threatening serious rashes, which are more frequently due to exceeding recommended doses of LMT or coadministration of valproic acid without dose adjustment.[11] In this context, the most common movement disorders secondary to LMT are ataxia (22%), tremor (4%), and speech disorder (3%);[11],[12] other abnormal movements are infrequently and in the majority of the times challenging in the clinical practice. This literature reviews to evaluate the clinical epidemiological profile, pathological mechanisms, and management of lamotrigine-associated movement disorders.


 » Methods Top


Search strategy

We searched six databases in an attempt to locate any and all existing reports on movement disorders secondary to lamotrigine published between 1993 and 2019 in electronic form. Excerpta Medica (Embase), Google Scholar, Latin American and Caribbean Health Sciences Literature (Lilacs), Medline, Scientific Electronic Library Online (Scielo), and Science Direct were searched. Search terms were “parkinsonism, tic, dyskinesia, dystonia, stuttering, myoclonus, restless legs syndrome, akathisia, tremor, chorea, restlessness, ataxia, ballism, hyperkinetic, hypokinetic, bradykinesia, movement disorder”. These terms were combined with “Lamotrigine, BW430C” [Supplementary Material].



Inclusion and exclusion criteria

Case reports, case series, original articles, letters to the editor, bulletins, and poster presentations published from 1993 to 2019 were included in this review with no language restriction. The two authors independently screened the titles and abstracts of all papers found from the initial search. Disagreements between the authors were resolved through discussion.

We excluded cases that the cause of the movement disorder was better explained by another diagnosis than an adverse event of lamotrigine. Cases that the individual motor symptoms not worsened by or were not related to lamotrigine were not included in the analysis. Reports that had more than one contributing factor to the movement disorder were evaluated based on the Naranjo algorithm to estimate the probability of the event occurring. Studies that were not accessible by electronic methods including after a formal request to the authors of the study by email were excluded. Also, reports that the individuals only developed tremor or ataxia after lamotrigine use were not included.

Data extraction

A total of 7441 papers were found; 6853 were irrelevant [Figure 3]. When provided, we extracted author, department, year of publication, country of occurrence, number of patients affected, lamotrigine indication including off-label uses, time from first lamotrigine-dose till movement disorder onset, time from lamotrigine withdrawal to symptoms improvement, patient's status at follow-up, and important findings of clinical history and management. The majority of the reports did not clearly describe the time of occurrence of symptoms after lamotrigine starting and the time from drug withdrawal to the improvement of the symptoms. The data were extracted by two independent authors, double-checked to ensure matching, and organized by whether the movement disorder was a side effect of the lamotrigine use.
Figure 3: Flow chart of the screening process

Click here to view


Definitions

The clinical characteristics and definitions of the movement disorders such as parkinsonism, tic, dyskinesia, dystonia, stuttering, myoclonus, restless legs syndrome, akathisia, tremor, chorea, restlessness, ataxia, ballism, hyperkinetic, hypokinetic, bradykinesia were obtained from the reference Jankovic and Tolosa.[13] The clinical diagnosis for the psychiatric conditions was obtained from the diagnostic and statistical manual of mental disorders (DSM-5).[14] The Naranjo algorithm was used for determining the likelihood of whether an adverse drug reaction was actually due to the drug rather than the result of other factors.[15] In the cases where the non-English literature was beyond the authors' proficiency (English, Portuguese, Spanish, Italian, French, and German), and the English abstract did not provide enough data, such as Japanese, Korean, Chinese, Russian, and Dutch, Google Translate service was used.[16]


 » Results Top


For the years 1993 and 2019, a total of 48 reports containing 108 cases who developed movement disorders secondary to LMT from 19 countries were reported [Table 1].[17],[18],[19],[20],[21],[22],[23],[24],[25],[26],[27],[28],[29],[30],[31],[32],[33],[34],[35],[36],[37],[38],[39],[40],[41],[42],[43],[44],[45],[46],[47],[48],[49],[50],[51],[52],[53],[54],[55],[56],[57],[58],[59],[60],[61],[62],[63],[64] [Figure 4] shows the number of reports associated with movement disorders and LMT shows throughout time. The origin was North American 57 cases, European 35, Asian 10, South American 4, and Australian in 2. The movement disorders associated with LMT found were 29 tics, 21 dyskinesias, 14 myoclonus, 13 parkinsonism, 10 dystonia, and 1 stuttering. The not clearly defined cases included 10 akathisia, 4 myoclonus, 4 cerebellar syndromes, 1 hypertonia, 1 dyskinesia, and an unknown number of dystonia cases.
Figure 4: Graphic showing the number of clinical reports of lamotrigine-associated movement disorder from 1993 to 2019

Click here to view
Table 1: Clinical reports of lamotrigine-associated movement disorders

Click here to view


The mean reported age was 33.34 years (age range: 1.574 years) and the median was 28 years. The male was the predominant sex in 53.84% of the cases (35/65). The most common LMT indication was epilepsy in 63.88% (46/72), followed by bipolar disorder (17). and Parkinson's disease (9). The mean LMT-dose at the movement disorder onset was 228 mg (dose range: 50800 mg).

The time from LMT start to the onset of movement disorder was defined in 53 cases; the time was less than 1 month in 13 cases, between 1 and 6 months in 30 cases, and 10 in more than 6 months (onset range: 2 days—2.91 years). The time from LMT withdrawal to complete recovery was reported in 31 cases; the time was within one month in 26 cases (recovery range: 1.5 days—4 months).

The most common management was the LMT withdrawal in 61% (44/72). The other options were the LMT maintenance, LMT-dose decrease, LMT-dose decrease followed by a progressive slow LMT-dose increase, or the starting of another medication such as Levodopa, risperidone, and benzodiazepines. A full recovery was observed in 93% of the individuals (54/58), the other 30 cases did not report the patient's follow-up.


 » Discussion Top


General

LMT is among the one hundred most commonly prescribed medications in the United States.[65] It is on the World Health Organization's list of essential medicines, the most effective and safest medicines needed in a health system.[66] Also, medicaid recently published the national average drug acquisition cost, and the amount has a wholesale cost of about less than five dollars a month per person.[67] Consequently, LMT is one of the best-selling and safety profile anticonvulsants that we have on the market today.

We can suppose a general presentation based on the 108 cases of LMT-associated movement disorder reported. In the majority of the cases, a young adult North American male with epilepsy presented to a neurology clinic. LMT was started as add-on therapy with small increases every week until 200-250mg. After about 1-6 months, the individual reported motor and vocal tics with some of them complaining of blepharospasms. The physician advised the LMT withdrawal. In the follow-up within 1 month, the patient had a full recovery.

Cases only reporting tremors and ataxia were excluded from the analysis due to unclear descriptions in clinical trials and be more suggestive than a complaining.[68] In the not clearly defined subgroup, the case reported by Buckley and coworkers probably was parkinsonism with ataxia, but due to insufficient data, we cannot conclude a diagnosis.[19] Some of the cases also reported cerebellar syndromes presenting with slurred speech, nystagmus, and ataxia.[35],[49] Also, although akathisia is a frequent central nervous system found in the clinical trials for FDA approval, we only find a study reporting, so probably this abnormal movement disorder is not as common as previously thought.[20]

Herein, we would like to discuss some of the movement disorders in subtopics to give a better comprehension of the data. [Figure 5] shows a resume of the hypothesized pathophysiological mechanisms that we proposed for the development of movement disorders following the use of LMT. Also, the figure shows that there is a relationship between the movement disorder and the LMT-dose; for example, tics may be associated with a glutamatergic mechanism, and in our study was observed that the tic reports have higher LMT doses when compared to the general data. Therefore, we can indirectly assume that the selective inhibition of the neurotransmitter is related to LMT-dose; this can be supported by hamster and rat models that this relation was already presupposed.[69],[70],[71]
Figure 5: Schematic diagram showing the resume of the hypothesized pathophysiological mechanisms of lamotrigine (LMT)-associated movement disorder (MD). Above, it is showing the MD associated with the neurotransmitter that LMT is related; below, the MD associated with the LMT-dose (low, moderate, high). DTN: dystonia; DKN: dyskinesia; MCL: myoclonus; PKN: parkinsonism

Click here to view


Tics

In the tic subgroup, the mean LMT-dose and the time from LMT start to movement disorder onset were higher than the general data. The distribution between the sexes was the same. The patients presented with motor, vocal, or motor and vocal tics. Some had vocal tic related to obsessive-compulsive disorder.[40] The majority of the motor tics involved the facial muscles, eye blinking, coughing, or sniffing. The tics were also described in the literature as drug-induced Tourettism.[42]

The most common management was drug withdrawal. But, the LMT-dose decrease was also effective to improve the symptoms.[59] Moreover, the rechallenge in a lower LMT-dose showed no reoccurrence of tics.[40] Therefore, we believe that before withdrawal LMT, a dose adjustment based on the benefits and adverse events with careful evaluation case-by-case can be done.

The pathophysiological mechanisms of tics are unclear, but probably dopamine plays an important role. This hypothesis can be supported by the presence of tics after central nervous system stimulants that release dopamine and the effectiveness in the treatment of tics by dopamine receptor antagonists.[31],[72] LMT is chemically structural different from most anticonvulsants and does not have any significant activity on dopamine transmission.[73] However, LMT influences the release of the glutamate/aspartate, which is the key excitatory input to the basal ganglia pathways [Figure 6].[74],[75] Moreover, this neurotransmitter can inhibit the dopamine release in the substantia nigra and striatum as was already shown in animal studies.[74] Also, it is worthy of mentioning that in brain autopsy studies in Tourette syndrome, low glutamate levels in the medial globus pallidus were observed.[76] So, the LMT decreases the glutamate release, which can lead to a facilitation of the movement, in a state of prokinetic effect, like tics.
Figure 6: Schematic diagram showing the glutamatergic pathways in the basal ganglia. 1: caudate and putamen; 2a: external globus pallidus (GP); 2b: internal GP; 3: thalamus; 4 subthalamus; 5a: substantia nigra (SN) pars compacta; 5b: SN pars reticulata; A: glutamatergic neurotransmission; B: gabaergic; C: dopaminergic

Click here to view


It is interesting that only some patients develop tic so may have a predisposition for this association.[42] Menezes et al. hypothesized that individuals with previous brain injury are more susceptible to developing tics secondary to LMT due to possible excitotoxin-mediated neuronal damage, which in their case series the majority of the individuals had some preexisting brain abnormality.[57]

Dyskinesias

The Dyskinesias (DKN) cases were poorly described with lacking information about the neurological examination and the times of movement disorder onset and recovery. The presentation was choreoathetotic or choreiform in almost all cases, except for only one that reported bilateral ballism.[61] Zesiewicz et al. reported DKN-symptoms after a rapid dosage increase (start with 100 mg/day).[63] The LMT rechallenge was not tried in any of the cases probably because the DKN-symptoms severely compromised the quality of life in the individuals reported.[27] The most frequent management was drug withdrawal; benzodiazepines were tried in one individual after LMT overdose, but the outcomes were not described.[46] It is noteworthy that LMT in patients with Huntington's disease showed significant improvement of choreiform hyperkinesias.[77]

An assumption for the mechanism of drug-induced DKN is an abnormal adaptation of the striatal organization leading to overactivation of the direct pathway.[78] This hypothesis is feasible for the development of LMT-induced DKN in some of the reported cases but does not explain those cases that the abnormal movement occurred in a short period of time.[63] In this way, we hypothesized that the decrease of GABA by LMT in the striatum, which can lead to an excess of dopamine and activation of the direct pathway, is probably the main neurotransmitter associated with DKN in the reported cases. This is supported by reports with schizophrenic patients showing reduced expression of glutamic acid decarboxylase, the key enzyme in GABA synthesis.[79] However, GABA can also be increased by LMT.[71]In this context, the excess of GABA can supersensitive the dopaminergic neurotransmission leading to the DKN-symptoms, which was already shown in rat models.[70] Thereby, both the increase and the decrease of GABA may explain the mechanism of the DKN secondary to LMT.

Myoclonus

The sex most prevalent in the myoclonus (MCL) subgroup was the female, which differs from the general records and the literature about drug-induced MCL that the sex ratio 1:1.[80] The individuals were using for a long time LMT before the occurrence of the abnormal movement. In the majority of the cases, the MCL was multifocal with a cortical source showed by epileptic electrodiagnostic studies; but in two cases with higher doses, the source was subcortical with a normal electroencephalogram.[17],[58]

The management was the LMT withdrawal in an important percentage of the subjects. LMT-dose reduction showed a decrease in the MCL frequency or even the complete recovery. Piracetam was attempted in one case without any improvement.[38] In another case after the occurrence of MCL, LMT-dose was reduced; after LMT-dose was slowly and progressively increased again without the development of new symptoms.[25] None of the reports used outpatient benzodiazepines, we believe that maybe a trial with clonazepam should be done to alleviate the symptoms and reduce the recovery time.[80] A large part of the cases did not report the recovery time, but those who described it was days-weeks, which is a long time for a disabling symptom like MCL.

The different sources of MCL can be explained by the variety of sodium channels with distinct localization, sensitivity, and binding properties to LMT.[81] It is possible that cortical neurons are more affected and sensitive to LMT, whereas inhibitory interneurons in the spinal cord and brainstem are vulnerable to cause MCL.[17],[82] Therefore, the glutamate and GABA balance could explain the origin of the abnormal movement; for example, when there is a greater inhibition to release GABA than glutamate, a relative excess of glutamate will occur and facilitate the occurrence of the jerks and even a status epilepticus. This hypothesis can be supported by animal studies that low to moderate LMT-dose was correlated with the lower release of GABA.[6] Furthermore, in the cases reported the LMT-dose was moderate in more than half of the cases.

Parkinsonism (PKN)

The population affected by Parkinsonism (PKN)-induced LMT was more than 20 years older than the general data, which can be explained by the age as an important component in this association.[83] But, Santens et al. described normal dopamine striatal uptake with ioflupane single-photon emission computed tomography.[54] The doses when PKN occurred were moderate and the time from LMT start till PKN onset was longer. LMT withdrawal was effective to improve the symptoms.

It is believed that there is an interaction between glutamatergic and dopaminergic neurotransmission. Soon after the discovery that LMT can reduce the release of glutamate, it was thought that LMT could have antiparkinsonian effects, but this was not confirmed in animals[84] or even humans[56] studies. In addition, the administration of high doses in the normal mice decreases spontaneous locomotor activity and causes posture and gait impairments.[85] In this way, the stabilization of presynaptic cell membranes and subsequent inhibition of glutamate/aspartate release may contribute to a decrease/increase of dopamine turnover[86] and locoregional differences of the glutamate[87] balance, in the same way as for tic-induced LMT.

Dystonia

The patients presented in decreased order of frequency with blepharospasms, oromandibular, cervical, and axial DTN. The LMT-doses related to DTN were lower when compared to the general data, but DTN is also more commonly found in LMT overdose in toxicologic studies.[88] The drug was withdrawn in almost all cases, except one that LMT-dose was reduced with symptoms improvement.[51] In two pediatric patients, the drug withdrawal only slightly alleviated DTN, as a result, levodopa was started, and showed rapid recovery of symptoms.[28]

The first reports of DTN secondary to LMT were observed in hamster models. The DTN was observed in lower doses of LMT and appears to be the movement disorder more sensible to LMT.[69] This data can be supported by the present review that revealed lower LMT-dose causing DTN. It was interesting that in the hamster there was no difference in prodystonic effect after parenteral or oral administration, which can be explained by the well-absorption oral via;[89] probably this adverse event will be associated with the coming LMT intravenous formulations. The decrease of glutamatergic transmission probably does not explain the DTN following LMT use because many experiments had already demonstrated antidystonic activity of glutamate receptor antagonists.[90] Therefore, we believe that the DTN is probably involved with the decrease of GABA leading to an interruption in the direct and indirect pathways; which probably predominant affects the indirect pathway,[91] and as a result, this disruption can increase the thalamocortical drive and eventually cause dystonia.[92]


 » Conclusion Top


LMT is associated with tics, DKN, MCL, PKN, DTN, stuttering, AKT, and DTN. The pathophysiological explanations for the LMT-induced movement disorders are probably related to GABA for DTN and DKN; GABA and Glutamate for MCL; glutamate for PKN and tic. One interesting fact is that the type of LMT-induced movement disorder may be associated with the LMT-dose. In the literature, the majority of the cases did not give a clear picture of the individuals; also, the times of movement disorder onset and recovery were not described. Future studies related to adverse effects with LMT need to evaluate the individuals in a prospective way to provide prognostic information about the development of primary movement disorders.

Financial support and sponsorship

Nil.

Conflicts of interest

There are no conflicts of interest.



 
 » References Top

1.
Risner M. The development of lamotrigine. Epilepsy Through the Ages Van Zuiden Communications, Netherlands 2001:339-53.  Back to cited text no. 1
    
2.
Peck AW. Clinical pharmacology of lamotrigine. Epilepsia 1991;32(Suppl 2):S9-S12.  Back to cited text no. 2
    
3.
Weisler RH, Calabrese JR, Bowden CL, Ascher JA, DeVeaugh-Geiss J, Evoniuk G. Discovery and development of lamotrigine for bipolar disorder: Astory of serendipity, clinical observations, risk taking, and persistence. J Affect Disord 2008;108:1-9.  Back to cited text no. 3
    
4.
Betchel NT, Saadabadi A. Lamotrigine. StatPearls [Internet]. StatPearls Publishing; 2018.  Back to cited text no. 4
    
5.
Pappagallo M. Newer antiepileptic drugs: Possible uses in the treatment of neuropathic pain and migraine. Clin Ther 2003;25:2506-38.  Back to cited text no. 5
    
6.
Braga MFM, Aroniadou-Anderjaska V, Post RM, Li H. Lamotrigine reduces spontaneous and evoked GABAA receptor-mediated synaptic transmission in the basolateral amygdala: Implications for its effects in seizure and affective disorders. Neuropharmacology 2002;42:522-9.  Back to cited text no. 6
    
7.
Coplan JD, Gopinath S, Abdallah CG, Berry BR. A neurobiological hypothesis of treatment-resistant depression - mechanisms for selective serotonin reuptake inhibitor non-efficacy. Front Behav Neurosci 2014;8:189.  Back to cited text no. 7
    
8.
Whirl-Carrillo M, McDonagh EM, Hebert JM, Gong L, Sangkuhl K, Thorn CF, et al. Pharmacogenomics knowledge for personalized medicine. Clin Pharmacol Ther 2012;92:414-7.  Back to cited text no. 8
    
9.
Dickens D, Owen A, Alfirevic A, Giannoudis A, Davies A, Weksler B, et al. Lamotrigine is a substrate for OCT1 in brain endothelial cells. Biochem Pharmacol 2012;83:805-14.  Back to cited text no. 9
    
10.
Zhang C, Kwan P, Zuo Z, Baum L. The transport of antiepileptic drugs by P-glycoprotein. Adv Drug Deliv Rev 2012;64:930-42.  Back to cited text no. 10
    
11.
Administration FaD. Lamictal® Accessdata2009 [cited 2019 12/16/2019]. Available from: https://www.accessdata.fda.gov/drugsatfda_docs/label/2009/022251,020764s029,020241s036lbl.pdf.  Back to cited text no. 11
    
12.
Binnie C, Boas WVE, Kasteleijn-Nolste-Trenite D, De Korte R, Meijer J, Meinardi H, et al. Acute effects of lamotrigine (BW430C) in persons with epilepsy. Epilepsia 1986;27:248-54.  Back to cited text no. 12
    
13.
Jankovic J, Tolosa E. Parkinson's Disease and Movement Disorders. Lippincott Williams and Wilkins; 2007.  Back to cited text no. 13
    
14.
Association AP. Diagnostic and Statistical Manual of Mental Disorders (DSM-5®). American Psychiatric Pub; 2013.  Back to cited text no. 14
    
15.
Naranjo CA, Busto U, Sellers EM, Sandor P, Ruiz I, Roberts E, et al. A method for estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981;30:239-45.  Back to cited text no. 15
    
16.
De Vries E, Schoonvelde M, Schumacher G. No longer lost in translation: Evidence that Google Translate works for comparative bag-of-words text applications. Polit Anal 2018;26:417-30.  Back to cited text no. 16
    
17.
Algahtani HA, Aldarmahi AA, Al-Rabia MW, Almalki WH, Bryan Young G. Generalized myoclonus and spasticity induced by lamotrigine toxicity: Acase report and literature review. Clin Neuropharmacol 2014;37:52-4.  Back to cited text no. 17
    
18.
Alkin T, Onur E, Ozerdem A. Co-occurence of blepharospasm, tourettism and obsessive-compulsive symptoms during lamotrigine treatment. Prog Neuropsychopharmacol Biol Psychiatry 2007;31:1339-40.  Back to cited text no. 18
    
19.
Buckley NA, Whyte IM, Dawson AH. Self-poisoning with lamotrigine. Lancet 1993;342:1552-3.  Back to cited text no. 19
    
20.
Carlson BX, Ketter TA, Sun W, Timko K, McQuade RD, Sanchez R, et al. Aripiprazole in combination with lamotrigine for the long-term treatment of patients with bipolar I disorder (manic or mixed): Arandomized, multicenter, double-blind study (CN138-392). Bipolar Disord 2012;14:41-53.  Back to cited text no. 20
    
21.
Catania S, Cross H, de Sousa C, Boyd S. Paradoxic reaction to lamotrigine in a child with benign focal epilepsy of childhood with centrotemporal spikes. Epilepsia 1999;40:1657-60.  Back to cited text no. 21
    
22.
Centorino MB, Catalano G, Catalano MC. Lamotrigine induced whole body tics: A case report and literature review. Curr Drug Saf 2016;11:189-91.  Back to cited text no. 22
    
23.
Cerminara C, Montanaro ML, Curatolo P, Seri S. Lamotrigine-induced seizure aggravation and negative myoclonus in idiopathic rolandic epilepsy. Neurology 2004;63:373-5.  Back to cited text no. 23
    
24.
Chiew AL, Cush K, Chan BS, editors. Prolonged delirium and abnormal movements in paediatric lamotrigine ingestion. Clinical Toxicology; 2013: Informa Healthcare 52 Vanderbilt Ave, New York, NY 10017 USA.  Back to cited text no. 24
    
25.
Corcuera PF, Pomarol E, Amann B, McKenna P. Myoclonus provoked by lamotrigine in a bipolar patient. J Clin Psychopharmacol 2008;28:248-9.  Back to cited text no. 25
    
26.
Crespel A, Genton P, Berramdane M, Coubes P, Monicard C, Baldy-Moulinier M, et al. Lamotrigine associated with exacerbation or de novo myoclonus in idiopathic generalized epilepsies. Neurology 2005;65:762-4.  Back to cited text no. 26
    
27.
Das KB, Harris C, Smyth DPL, Cross JH. Unusual side effects of lamotrigine therapy. J Child Neurol 2003;18:479-80.  Back to cited text no. 27
    
28.
Ebrahimi HA, Ebrahimi S. Dopa-responsive dystonia subsequent tolamotrigine administration. Iran J Pharmacol Ther 2013;12:39-41.  Back to cited text no. 28
    
29.
Eleftheriou G, Butera R, Zavaritt A, Varesio V, Bonomi M, Manzo L, et al., editors. Dystonic effects and false increase in lactate levels after lamotrigine poisoning. Clinical Toxicology; 2009: Informa Healthcare 52 Vanderbilt Ave, New York, NY10017 USA.  Back to cited text no. 29
    
30.
Fleurat M, Smollin C. Case files of the University of California San Francisco Medical Toxicology Fellowship: Lamotrigine toxicity. J Med Toxicol 2012;8:52-8.  Back to cited text no. 30
    
31.
Frost M, Ritter F, Hoskin C, Mims J, Espe-Lillo J. Movement disorder associated with lamotrigine treatment in children and adolescents. Epilepsia 1996;37:32.  Back to cited text no. 31
    
32.
Grosso S, Ferranti S, Gaggiano C, Grande E, Loi B, Di Bartolo R. Massive lamotrigine poisoning. A case report. Brain Dev 2017;39:349-51.  Back to cited text no. 32
    
33.
Guerrini R, Belmonte A, Parmeggiani L, Perucca E. Myoclonic status epilepticus following high-dosage lamotrigine therapy. Brain Dev 1999;21:420-4.  Back to cited text no. 33
    
34.
Angus-Leppan H, Nash A, Pilling R. Recognising acute lamotrigine induced Tourette's syndrome in adults. Sci J Res Rev 2019;1.doi: 10.33552/SJRR.2019.01.000515.  Back to cited text no. 34
    
35.
Hajiali F, Nassiri-Asl M. Report of severe menorrhagia following the maximum amount of lamotrigine overdose. Iran J Pharm Res 2015;14:1289-93.  Back to cited text no. 35
    
36.
Ho G, Swartz B, Kaplan L, editors. Lamotrigine-induced parkinsonism: Report of three cases in non-Parkinson's patients. Annals of Neurology; 1997: Lippincott-Raven Publ 227 East Washington SQ, Philadelphia, PA 19106.  Back to cited text no. 36
    
37.
Inaba T, Sogawa R, Mizoguchi Y, Tateishi H, Kunitake Y, Kato TA, et al. Lamotrigine rechallenge in treatment-resistant bipolar disorder. Prim Care Companion CNS Disord 2018;20:17m02231.  Back to cited text no. 37
    
38.
Janszky J, Rásonyi G, Halász P, Olajos S, Perényi J, Szûcs A, et al. Disabling erratic myoclonus during lamotrigine therapy with high serum level--report of two cases. Clin Neuropharmacol 2000;23:86-9.  Back to cited text no. 38
    
39.
Kankirawatana P, Dure LS 4th, Bebin EM. Chorea as manifestation of epilepsia partialis continua in a child. Pediatr Neurol 2004;31:126-9.  Back to cited text no. 39
    
40.
Kemp DE, Gilmer WS, Fleck J, Dago PL. An association of intrusive, repetitive phrases with lamotrigine treatment in bipolar II disorder. CNS Spectr 2007;12:106-11.  Back to cited text no. 40
    
41.
Kim DG, Oh SH, Kim OJ. A case of lamotrigine-induced excessive involuntary eye blinking. JClin Neurol (Seoul, Korea) 2007;3:93-5.  Back to cited text no. 41
    
42.
Lombroso CT. Lamotrigine-induced tourettism. Neurology 1999;52:1191-4.  Back to cited text no. 42
    
43.
Lu D, Lin X, Liu X, Su L. Lamotrigine-induced facial tic in a pediatric bipolar disorder patient. J Child Adolesc Psychopharmacol 2013;23:583-4.  Back to cited text no. 43
    
44.
Marrero-Gonzalez PC, Ruano OL, Catalano G, Catalano MC. Dystonia associated with lamotrigine therapy: Acase report and review of the literature. Curr Drug Saf 2014;9:60-2.  Back to cited text no. 44
    
45.
Mathur R, Medhi D, Lihite R, Lahkar M. Lamotrigine induced dystonia in a patient with bipolar affective disorder. Brain DisordTher 2016;5.doi: 10.4172/2168-975X.1000212.  Back to cited text no. 45
    
46.
Miller M, Patel M, Tai W, Olson K. Choreatic dyskinesia following lamotrigine overdose. J Toxicol Clin Toxicol 2001;39:499-505.  Back to cited text no. 46
    
47.
Miller MA, Levsky ME. Choreiform dyskinesia following isolated lamotrigine overdose. J Child Neurol 2008;23:243.  Back to cited text no. 47
    
48.
Moore PW, Donovan JW, Burkhart KK, Haggerty D. A case series of patients with lamotrigine toxicity at one center from 2003 to 2012. Clin Toxicol (Phila) 2013;51:545-9.  Back to cited text no. 48
    
49.
Moreira B, Thomé-Souza S, Valente K. Late side-effects of valproate and lamotrigine. J Epilepsy Clin Neurophysiol 2007;13:187-9.  Back to cited text no. 49
    
50.
Musiek ES, Anderson CT, Dahodwala NA, Pollard JR. Facial tic associated with lamotrigine in adults. Mov Disord 2010;25:1512-3.  Back to cited text no. 50
    
51.
Rajda CW A, Varga ET, Vécsei L. Seizure, dystonia or something else? - Case report. Controversies Neurol 2015;2015:1.  Back to cited text no. 51
    
52.
Rosenhagen MC, Schmidt U, Weber F, Steiger A. Combination therapy of lamotrigine and escitalopram may cause myoclonus. J Clin Psychopharmacol 2006;26:346-7.  Back to cited text no. 52
    
53.
Sabolek M, Runge U. Lamotrigine induced dyskinesia in Parkinson's disease. Eur J Neurol 2010;17:e37.  Back to cited text no. 53
    
54.
Santens P, Claeys I, Vonck K, Boon P. Parkinsonism due to lamotrigine. Mov Disord 2006;21:2269-70.  Back to cited text no. 54
    
55.
Seemüller F, Dehning S, Grunze H, Müller N. Tourette's symptoms provoked by lamotrigine in a bipolar patient. Am J Psychiatry 2006;163:159.  Back to cited text no. 55
    
56.
Shinotoh H, Vingerhoets FJ, Lee CS, Uitti RJ, Schulzer M, Calne DB, et al. Lamotrigine trial in idiopathic parkinsonism: Adouble-blind, placebo-controlled, crossover study. Neurology 1997;48:1282-5.  Back to cited text no. 56
    
57.
Sotero de Menezes MA, Rho JM, Murphy P, Cheyette S. Lamotrigine-induced tic disorder: Report of five pediatric cases. Epilepsia 2000;41:862-7.  Back to cited text no. 57
    
58.
Tombini M, Pellegrino G, Assenza G, Di Lazzaro V. De novo multifocal myoclonus induced by lamotrigine in a temporal lobe epilepsy case. J Neurol Sci 2017;373:31-2.  Back to cited text no. 58
    
59.
Vance C, Kanner A, Smith M. Sydenham's-like picture and tourettism as related to lamotrigine toxicity. Epilepsia 2004;45:1361.  Back to cited text no. 59
    
60.
Verma A, Miller P, Carwile ST, Husain AM, Radtke RA. Lamotrigine-induced blepharospasm. Pharmacotherapy 1999;19:877-80.  Back to cited text no. 60
    
61.
Yetimalar Y, Seçkin M, Seçil Y, Başoğlu M. Lamotrigine-induced bilateral ballism. Mov Disord 2007;22:1832-3.  Back to cited text no. 61
    
62.
Zadikoff C, Munhoz RP, Asante AN, Politzer N, Wennberg R, Carlen P, et al. Movement disorders in patients taking anticonvulsants. JNeurolNeurosurgPsychiatry 2007;78:147-51.  Back to cited text no. 62
    
63.
Zesiewicz TA, Sullivan KL, Hauser RA. Chorea induced by lamotrigine. J Child Neurol 2006;21:357-8.  Back to cited text no. 63
    
64.
Zipp F, Bürklin F, Stecker K, Baas H, Fischer PA. Lamotrigine in Parkinson's disease--Adouble blind study. J Neural Transm Park Dis Dement Sect 1995;10:199-206.  Back to cited text no. 64
    
65.
DrugStats C. The Top 300 of 2019. ClinCalc 2019 [12/16/2019]. Available from: https://clincalc.com/DrugStats/Top300Drugs.aspx.  Back to cited text no. 65
    
66.
WHO. WHO model list of essential medicines. 20th list. World Health Organization; 2017 [12/16/2019]. Available from: https://www.who.int/medicines/publications/essentialmedicines/20th_EML2017.pdf?ua=1. [Last accessed on 2020 Jun 05].  Back to cited text no. 66
    
67.
Medicare. National Average Drug Acquisition Cost.Data.Medicaid.gov; 2019 [12/16/2019]. Available from: https://data.medicaid.gov/Drug-Pricing-and-Payment/NADAC-as-of-2019-11-27/qjsh-shte. [Last accessed on 2020 Jun 05].  Back to cited text no. 67
    
68.
Messenheimer J, Mullens EL, Giorgi L, Young F. Safety review of adult clinical trial experience with lamotrigine. Drug Saf1998;18:281-96.  Back to cited text no. 68
    
69.
Richter A, Löschmann PA, Löscher W. The novel antiepileptic drug, lamotrigine, exerts prodystonic effects in a mutant hamster model of generalized dystonia. Eur J Pharmacol 1994;264:345-51.  Back to cited text no. 69
    
70.
Sivam SP, Hudson PM, Tilson HA, Hong JS. GABA and dopamine interaction in the basal ganglia: Dopaminergic supersensitivity following chronic elevation of brain gamma-aminobutyric acid levels. Brain Res1987;412:29-35.  Back to cited text no. 70
    
71.
Cunningham MO, Jones RS. The anticonvulsant, lamotrigine decreases spontaneous glutamate release but increases spontaneous GABA release in the rat entorhinal cortex in vitro. Neuropharmacology 2000;39:2139-46.  Back to cited text no. 71
    
72.
Golden GS. The effect of central nervous system stimulants on Tourette syndrome. AnnNeurol1977;2:69-70.  Back to cited text no. 72
    
73.
Leach M. Lamotrigine: Mechanisms of action. Antiepileptic Drugs 1995:861-9.  Back to cited text no. 73
    
74.
Albin RL, Young AB, Penney JB. The functional anatomy of basal ganglia disorders. Trends Neurosci1989;12:366-75.  Back to cited text no. 74
    
75.
Gerlach M, Gsell W, Kornhuber J, Jellinger K, Krieger V, Pantucek F, et al. A post mortem study on neurochemical markers of dopaminergic, GABA-ergic and glutamatergic neurons in basal ganglia-thalamocortical circuits in Parkinson syndrome. Brain Res1996;741:142-52.  Back to cited text no. 75
    
76.
Anderson GM, Pollak ES, Chatterjee D, Leckman JF, Riddle MA, Cohen DJ. Postmortem analysis of subcortical monoamines and amino acids in Tourette syndrome. Adv Neurol 1992;58:123-33.  Back to cited text no. 76
    
77.
Shen Y-C. Lamotrigine in motor and mood symptoms of Huntington's disease. World J Biol Psychiatry 2008;9:147-9.  Back to cited text no. 77
    
78.
Lepping P, Delieu J, Mellor R, Williams JHH, Hudson PR, Hunter-Lavin C. Antipsychotic medication and oxidative cell stress: Asystematic review. J Clin Psychiatry 2011;72:273-85.  Back to cited text no. 78
    
79.
Akbarian S, Kim JJ, Potkin SG, Hagman JO, Tafazzoli A, Bunney WE Jr, et al. Gene expression for glutamic acid decarboxylase is reduced without loss of neurons in prefrontal cortex of schizophrenics. Arch Gen Psychiatry 1995;52:258-66.  Back to cited text no. 79
    
80.
Sutter R, Ristic A, Rüegg S, Fuhr P. Myoclonus in the critically ill: Diagnosis, management, and clinical impact. Clin Neurophysiol 2016;127:67-80.  Back to cited text no. 80
    
81.
Hains BC, Waxman SG. Sodium channel expression and the molecular pathophysiology of pain after SCI. Prog Brain Res 2007;161:195-203.  Back to cited text no. 81
    
82.
Escayg A, Goldin AL. Sodium channel SCN1A and epilepsy: Mutations and mechanisms. Epilepsia 2010;51:1650-8.  Back to cited text no. 82
    
83.
Tysnes O-B, Storstein A. Epidemiology of Parkinson's disease. J Neural Transm (Vienna) 2017;124:901-5.  Back to cited text no. 83
    
84.
Brodie MJ. Lamotrigine--An update. Can J Neurol Sci 1996;23 (4 Suppl 2):S6-9.  Back to cited text no. 84
    
85.
Kaur S, Starr M. Motor effects of lamotrigine in naive and dopamine-depleted mice. Eur J Pharmacol 1996;304:1-6.  Back to cited text no. 85
    
86.
Vriend J, Alexiuk NA. Lamotrigine inhibits the in situ activity of tyrosine hydroxylase in striatum of audiogenic seizure-prone and audiogenic seizure-resistant Balb/c mice. Life Sci 1997;61:2467-74.  Back to cited text no. 86
    
87.
Ahmad S, Fowler LJ, Whitton PS. Effect of acute and chronic lamotrigine on basal and stimulated extracellular 5-hydroxytryptamine and dopamine in the hippocampus of the freely moving rat. Br J Pharmacol 2004;142:136-42.  Back to cited text no. 87
    
88.
Lofton AL, Klein-Schwartz W. Evaluation of lamotrigine toxicity reported to poison centers. Ann Pharmacother 2004;38:1811-5.  Back to cited text no. 88
    
89.
Miller AA, Wheatley P, Sawyer DA, Baxter MG, Roth B. Pharmacological studies on lamotrigine, a novel potential antiepileptic drug: I. Anticonvulsant profile in mice and rats. Epilepsia 1986;27:483-9.  Back to cited text no. 89
    
90.
Richter A, Fredow G, Löscher W. Antidystonic effects of the NMDA receptor antagonists memantine, MK-801 and CGP 37849 in a mutant hamster model of paroxysmal dystonia. Neurosci Lett 1991;133:57-60.  Back to cited text no. 90
    
91.
Krystkowiak P, Martinat P, Defebvre L, Pruvo JP, Leys D, Destée A. Dystonia after striatopallidal and thalamic stroke: Clinicoradiological correlations and pathophysiological mechanisms. JNeurolNeurosurgPsychiatry 1998;65:703-8.  Back to cited text no. 91
    
92.
Pitton Rissardo J, Fornari Caprara A. Comment: Dystonia and asterixis in acute thalamic infarct: Proposed mechanism. Ann Mov Disord 2019;2:138-9.  Back to cited text no. 92
    


    Figures

  [Figure 1], [Figure 2], [Figure 3], [Figure 4], [Figure 5], [Figure 6]
 
 
    Tables

  [Table 1]



 

Top
Print this article  Email this article
   
Online since 20th March '04
Published by Wolters Kluwer - Medknow